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Abstract
Primary Sjögren’s syndrome (pSS) is an autoimmune disease, which dominates the
symptoms resulting from inflammatory infiltrates in exocrine glands. Frequently, pa‐
tients complain of a feeling of sand under the eyelids, eye irritation, and red eye caused
by a decrease in tear secretion. The ophthalmic examination beyond lowering the secre‐
tion of tears in Schirmer’s test evaluation in cases with a significant intensification of dry
eye disease (DED) can be visualized by measuring ocular staining score (OSS) using lissa‐
mine green and fluorescein staining. OSS can demonstrate the degree of damage to the
corneal surface. It is known that keratoconjunctivitis sicca (KCS) in pSS is not only limit‐
ed to the complaints of unpleasant feeling of sand under the eyelids but also can lead to
serious corneal damage and decreased vision even to blindness. And between the others,
complications of KCS in pSS must be replaced with an increased susceptibility to infec‐
tion. We should also pay attention to possible co-infection with Epstein-Barr virus (EBV)
virus and bacterial co-infections, e.g., Chlamydia pneumoniae, Staphylococcus aureus, or la‐
tent conjunctival infections Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma
urealyticum in group of patients with DED, not only in pSS group. Another issue is simul‐
taneous with hepatitis C virus (HCV) infection coexistance of clinical and laboratory fea‐
tures of Sjogrens syndrome and accompanying this situation clinical signs of KCS. To
sum up symptoms of KCS in primary Sjögren’s syndrome and in all patients with DED
should be evaluated individually and should take into account the increased risk of infec‐
tion among these patients.
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1. Introduction
Primary Sjögren’s syndrome (pSS) is an autoimmune disease in which the symptoms resulting
from inflammatory infiltrates in exocrine glands dominate. Frequently, patients complain of
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a feeling of sand under the eyelids, eye irritation, and red eye caused by a decrease in tear
secretion. In pSS, other exocrine glands could be affected—among them: salivary glands,
pancreas, vaginal mucous membranes, and glands of gastrointestinal tract or situated in
bronchial tree. The patient may complain of dry mouth, dry vagina, and inflammation of the
gastric and esophageal reflux. Dry cough may also occur. In the course of pSS interstitial
changes in the lungs may occur with a progressive reduction of lung function and a failure of
cardiovascular system (in conjunction with the development of right ventricular failure and
pulmonary hypertension). Autoimmune inflammatory process may also involve peripheral
and central nervous system, including cranial nerves, with symptoms of mixed sensory and
motor neuropathy or multiple sclerosis (MS)-like symptoms. In pSS, B lymphocytes (B-cells)
play a key role, with their hyperreactivity, leading to the overproduction of autoantibodies.
Through the interaction between the cells, stimulation reaches T lymphocytes (T-cells), which
are the first to form infiltrates in exocrine glands. The gradual destruction of the exocrine
glands by the inflammation and by the autoimmune process causes the above- described
symptoms [1].
2. Epidemiology
The epidemiology data of dry eye symptom (DES) reveal that it affects from 5 to 35% of the
population. Such discrepancy in the assessment of the frequency of the DES occurrence might
be the effect of using different dry eye definitions in each of the studies, as well as the research
being performed on different ethnic populations. The data given by the Women’s Health Study
indicate that Hispanics and Asians display greater predisposition to more severe symptoms
of dry eye than Caucasians [2]. The incidence of Sjögren’s syndrome, in which DES is a
dominant symptom, may also be underestimated. There are no accurate records on the
prevalence of this disease, with its milder course prone to be undiagnosed [3,4]. It is estimated
that pSS occurs in 0.1–3.0% of the general population. The disease is more common for women
(female/male ratio 9:1), affecting mainly individuals between the age of 40 and 60, with the
disease most frequently occurring around 50 years of age [5].
3. Outline pathogenesis
The pathogenesis of the disease is not entirely clear and factors responsible for its development
are still being sought. It is recognized that environmental or endogenous antigens trigger an
inflammatory response in susceptible individuals. Among the environmental factors, several
viral infections are considered as primary pSS cause: Epstein-Barr virus (EBV), human T-cell
lymphotrophic virus type-1 (HTLV-1), cytomegalovirus (CMV), and hepatitis C virus (HCV)
[5–7]. These infections may result in the epithelial barrier damage and the release of autoan‐
tigens from the affected epithelial cells. In the case of individual genetic predisposition to pSS,
the autoimmune process may develop, involving both mechanisms of innate and adaptive
immunity. Genetic factors responsible for the predisposition to pSS development include the
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presence of HLA-B8, HLA-DW3, HLA-DR3, and DRw52 genes; polymorphism of interferon
regulatory factor 5 (IRF 5) gene may also play similar role [1,8]. The release of autoantigens
triggers innate immunity through the activation of epithelial (EC) and dendritic cells (DC). DC
stimulation promotes interferon I and II pathways; DCs also produce IL-12, which activates
natural killer cells (NKCs) and stimulates Th1 cells. Both NKC and Th1 cells secrete interferon
gamma (INF-γ), responsible for the tissue damage and stimulating the secretion of B cell
activation factor (BAFF). BAFF is produced by T and B cells—both activated by DC; BAFF
production is also strongly stimulated by interferon (IFN)-α, released by pDC (plasmocytoid
dendritic cells). Moreover, the activation of innate response by Toll-like receptors (TLR-9, TLR-
7) additionally increases the secretion of BAFF. This overproduction of BAFF can cause
constant stimulation of B cells through different pathways and causes the loss of self-tolerance
by T and B cells, overproduction of immunoglobulins, of autoantibodies (predominantly SS-
A, SS-B) in particular, and the formation of germinal centres (GC) in the target organs. The
affected tissues (especially the salivary glands) display the overexpression of cytokines such
as tumor necrosis factor (TNF), lymphotoxin, CXC, and chemokines (ligand 13, 9, 21). This
process can lead to the development of lymphoma. The occurrence of primarily marginal zone
B-cell lymphoma (MZBCL) has been observed in about 8% of pSS patients—40-fold frequency
of the MZBCL in the healthy population [9,10]. The scheme of pathogenesis of pSS is shown
on figure1.
*Triggering factors as viral and bacterial infections, UVA (ultraviolet-A radiation), hormones, genetic predisposition
DC-dendritic cell, pDC plasmocytoid DC cell, IFN-γ- interferon gamma, TLRs- Toll-like receptors, IL-12- interleukine
12, TH1-type1 helper cell, BAFF- B cell activating factor, NK-cell natural killer cell
Figure 1. Scheme of pathogenesis [1, 5]
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The symptoms of primary Sjögren’s syndrome are not homogenous. The autoimmune process
involving the epithelium affects many systems and organs, so its manifestations can be very
diverse. Symptoms can be divided into two primary groups: common ones, such as dry eyes
and mouth, and less frequent symptoms, such as peripheral neuropathy with legs numbness
and weakness—with reduced or without reflexes, dysesthesia, feeling of temperature, and
vibration. Neurological symptoms may also indicate the seizure of the autonomic nervous
system with cardiac arrhythmias or gastrointestinal motility disorder. In the pSS, trigeminal
neuralgia and seizure of various nerves (“multiple mononeuropathy”) may also occur. The
central nervous system can also be involved in pSS therefore myelitis with weakness of limbs
and disturbances of urination may occur. Neurological symptoms can also suggest MS, which
leads to misdiagnosis. The types of symptoms in pSS are presented in Table 1.
Common symptoms Less common symptoms/organ involvement
xerophtalmia
xerostomia
troubles with swallowing
dental caries
artralgia
arthritis (non-erosive)
myalgia
fatigue
general weakness
weight loss
fever
Reynaud’s phenomenon
depression
anxiety
intestinal like disease (ILD)
bronchitis
dysphagia, gastrointestinal reflux
chronic gastritis
symptoms of PBC (primary billary cirrhosis) and AIH
(autoimmune hepatitis)
pericarditis
pulmonary hypertension
celiac-like diseas
distal renal tubular acidosis (RTA type 1)
nepritis/glomerulonephritis
chronic renal insufficiency
vasculitis
peripheral polyneuropathy,
cranial neuropathy,
mononeuritis multiplex
sensorineural hearing loss
SM-like syndrome
Table 1. Symptoms of pSS
Keratoconjunctivitis sicca (KCS) is the most frequent cause of complaints from the organ of
sight of patients with Sjogren’s syndrome, although it can be present in a number of other
diseases [11]. KCS is caused by a decreased tear production or increased tear film evaporation.
It manifests itself with a feeling of dryness— described as a sandy-gritty eye irritation—
burning, stinging, and feeling of tired eyes. In severe cases, the patients suffer from pain,
redness, or even decreased vision. The decreased tear production affects the overall reduction
of tear secretin as well as limits the aqueous phase of the tears. The causes of DES and
complications associated with KCS are presented in Tables 2 and 3.
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Primary  Sjogren’s  syndrome  may  be  associated  with  other  autoimmune  diseases.  Their
simultaneous presence can influence both the course and the prognosis of the disease. The
most common coexisting diseases are presented in Table 4.
The initial symptoms of an infection in dry eye syndrome—the eye pain, burning, eye redness
—can be associated with symptoms of dryness and aseptic KCS, as well as with an incipi‐
ent infection. However, when the pain and red eye are accompanied by a purulent excretion
—a bacterial infection should be suspected. Viral infections primarily cause an eye pain and
intense redness. These symptoms may also be associated with general symptoms of infec‐
tions such as muscle pain, fever, and fatigue. The diagnosis and treatment are determined
by the result of the ophthalmological examination.
Keratoconjunctivitis sicca symptoms – conditions and diseases
Environmental factors as dust, smoke, dry air, aircondition,
Behavior : working at the computer, watching television
long - causing less frequent blinking
Contact lenses
Age - related dry eye (ARDE)
Menopause (low level of estrogens)
Using drugs : antihistamines, β-blockers, diuretics,
antispasmodics,
diuretics, psychotropic
Vitami A deficiency
Allergic conjunctivitis
Sarcoidosis
Lymphoma
Graft versus host disease (GvHD)
Autoimmune deficiency (AIDS)
Diabetes
Trachoma (cause chlamydia trachomatis)
VII cranial nerve damage
Meibomian gland dysfunction
Reflex motor block (central demage of VII cranial nerve)
Reflex sensory block (trigeminal nerve denervation)
Refractive surgery : laser assisted keratomileusis (LASIK); photorefractive keratoplasty (PRK)
Table 2. Keratoconjunctivitis sicca —not only symptom of pSS
Eye problems in primary Sjögren’s syndrome
discomfort
pain
red eye
conjunctivitis
corneal erosions,
filamentary keratitis,
corneal ulcers
decreased vision
Table 3. Eye complications associated with KCS
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The diseases coexisting with p SS
Autoimmune Thyroid Disease (AITD) - Haschimoto disease
Intestinal Lung Disease (ILD)
Primary Billary Cirrhosis (PBC)
Autoimmune hepatitis (AIH)
Cryoglobulinemia
Autoimmune pancreatitis (AIP)
Distal renal tubular acidosis (RTA)
Sclerosis-multiplex like syndrome
Table 4. The diseases coexisting with p SS
4. Risk of eye infections in KCS
The conjunctivitis and changes in the cornea in the pSS are aseptic, yet coexisting infections
that may play a part in the development and course of the pSS, KCS in particular. Due to the
large differences in estimating the incidence and prevalence of dry eye syndrome (from 5 to
35%) and due to differences in the frequency of recognition of Sjögren’s syndrome, it is difficult
to accurately estimate the rate of incidence of sicca syndrome associated with eye infections.
However, impaired humidification of the eye and related development of KCS undoubtedly
significantly increase the risk of bacterial contamination, compared with the normal popula‐
tion.
Among viral infections, EBV plays an important role, which is not limited to the above-
mentioned impact on the immune system and lymphocytes. The EBV may be a separate,
independent cause of the dry eye syndrome because the infection affects mucosal surfaces and
lymphoid tissues. The EBV presence persists in ocular surface epithelia, following primary
infection and may cause dacryoadenitis, which leads to abnormal tear secretion [12,13].
Although no direct link between the occurrence of KCS and EBV infection has been established,
the influence of EBV on patient’s immune status could cause the development of symptoms
of dryness. Apart from EBV, other viral infections, which may contribute to the occurrence of
KCS and clinical picture of Sjogren’s disease, include in particular HCV, human T-cell
lymphotropic virus (HTLV), Human (HSV-1), and HIV [7,14]. HCV infection may be respon‐
sible for the incidence of ocular symptoms in the course of pSS, such as KCS retinopathy,
scleritis, and keratitis. In HSV-1 infection, besides KCS, keratitis, blepharitis, conjunctivitis,
uveitis, and retinitis may develop [15]. Viral agents involved in pathogenesis of pSS, EBV in
particular, can be simultaneously responsible for causing KCS, conjunctivitis, and reducing
resistance of the corneal epithelium.
Although viruses play a significant role in the pathogenesis of pSS, the importance of bacterial
co-infections, e.g., Chlamydia pneumonia in the course of pSS should not be underestimated [16].
It is known that a tear film has antimicrobial properties, whereas the normal ocular surface
contains bacterial flora, including Staphylococcus epidermidis, S. aureus, and diphteroides (e.g.,
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Corynebacterium diphtheriae and Propionibacterium acnes). However, in patients with DESs and
treated with immunosuppressants, such therapy, along with dryness and cornea damage,
results in increased susceptibility to common bacterial infections. In the diagnosis of ocular
symptoms, bacterial keratitis should come under consideration. This may more likely be
caused by S. aureus, Haemophilus influenzae, Streptococcus pneumoniae and, in the case of use of
contact lenses, more often Pseudomonas aeruginosa. Hori et al. [17] showed that infections with
bacteria resistant to fluoroquinolones (Staph. sp. Staph. aureus) are more common in patients
with dry eye syndrome, although among dry eye patients, regardless of use of punctual plugs
or topical steroids, there were no differences in bacteria isolated from conjunctiva.
In the diagnosis of pSS, it must also be considered that some of the commonly known infections,
such as HIV, tuberculosis, leprosy, spirochetes, hepatitis A, B, or C, parvovirus B19, Dengue
fever, malaria, subacute bacterial endocarditis, and HIV can mimic Sjögren’s syndrome with
symptoms of eye dryness. Prognosis for the infection occurring in the course of a dry eye in
Sjögren’s syndrome is more serious compared to the infection cases with no additional risk
factors present. This results from the, pre-existing in Sjögren's syndrome, surface damage and
use of immunosuppressive therapy in this disease. Therefore, patients with Sjögren's syn‐
drome and a coexisting bacterial infection of the eye belong to a group in which immediate
antibiotic therapy should be considered.
5. Cicatrizing conjunctivitis as complication of dry eye disorders
In course of pSS, a slow progressive cicatrizing conjunctivitis (PCC) may also develop with
complications such as an impairment of vision (and even blindness), pain, and corneal damage.
Cicatrizing is a type of scarring, which can occur as a complication of dry eye accompanied by
autoimmune diseases like Sjögren's syndrome or ocular cicatrical pemphigoid. Chronic
conjunctival cicatrization (CCC) can also occur as an effect of thermal and chemical burns,
postinfectious conjunctivitis, ocular rosacea, atopic keratitis, graft versus host disease, and
Stevens-Johnson syndrome (in the latter case prognosis being particularly poor) [18,19]. The
presence of cicatrizing conjunctivitis predisposes to microbial keratitis, especially in Sjögren’s
syndrome. Ormerod et al. [20] described that almost 50% of studied Sjögren’s syndrome
patients had microbial keratitis as a complication of sterile ulcerations and were subject to
recurrent infections. Most common infection in that group was Gram-positive bacteria such
as S. aureus. It was also noted that patients with conjunctival cicatrization (CC) in the course
of Sjögren’s syndrome had higher complication rate compared to those in which CC was
caused by other factors; such complications included corneal perforation, endophthalmitis,
and descementocele. Interestingly, the authors also point out that a long-term therapy with
topical corticosteroids and application of bandage contact lenses used in refractive surgery
enhanced a risk of microbial keratitis.
Treatment strategies in CC depend on the cause of the underlying disease. In case of microbial
keratitis, topical antibiotic use is recommended.
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6. Diagnosis criteria of Sjogren’s syndrome
Over the years (since 2002), pSS recognition has been based on the criteria set by American-
European Consensus Group (AECG) in which both Schirmer’s test and tear break-up time
(BUT) results are assessed. According to former pSS criteria, the examination of salivary
secretory function was assessed by measuring minute salivation and evaluation in sialogra‐
phy. From 2012, the American College of Rheumatology (ACR) has proposed new diagnostic
criteria that are presented in Table 5 [21–23].
Sjögren’s Syndrome criteria ACR 2012
1. Positive serum anti-SSA/Ro and/or anti-SSB/La or positive rheumatoid factor and ANA titer 1:320
2. Labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a focus score 1 focus/4 mm2
3. Ocular staining score 3 proving keratoconjunctivitis sicca *
Exclusions:
Head and neck radiation treatment
Active Hepatitis C infection
Acquired immunodeficiency syndrome
Sarcoidosis
Amyloidosis
Graft versus host disease (GVHD)
IgG4-related disease (IgG4-RD)
*Excluding the patients using daily eye drops for glaucoma and who has had corneal surgery or cosmetic eyelid surgery
in the last 5 years
Table 5. Diagnostic criteria of Sjögren’s syndrome
It was found that most changes associated with KCS can be demonstrated using the Lissamine
green and fluorescein stainings. Both stainings are used for establishing ocular staining score
(OSS), determined for each eye separately and used to identify the degree of change in the
conjunctiva (Lissamine green) as well as the damage to the cornea (fluorescein) [21]. The slit
lamp examination reveals damage to the cornea, but using staining allows for a quantitative
and qualitative assessment of these changes. Another test which can be useful in the evaluation
of dry eye is a tear osmolality test. However, this test is not included in the criteria for pSS
diagnosis [24,25].
The newly proposed criteria also apply to the early stage of diagnosis, when no evidence of
the presence of autoantibodies for ribonucleoproteins anti-Ro (SS-A) and anti-La (SS-B) is
available. In such a case, the mutual presence of rheumatoid factor (RF) and of antinuclear
antibody (ANA, the latter in titer of no less than 1: 320) proves the diagnosis [25].
The important part of establishing pSS diagnosis is confirming the presence of typical changes
in histopathology material from minor salivary gland biopsy (MSGB)— mononuclear inflam‐
matory cells form focal infiltrates of more than 50 cells in 4 mm2 of glandular section. The so-
called focus score (FS) is based on the assessment of number of such changes in the tested
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material. The presence of one or more foci is considered as a positive result. Primary Sjogren’s
syndrome may be accompanied by other than SS-A, SS-B, or RF autoantibodies [26,27]. Most
common pSS-specific antibodies, also associated with other autoimmune diseases, are
presented in Table 6.
Autoantibodies in pSS
diagnostic hallmark:
Anti SS-A (Ro)
Anti-SS-B (La)
Autoantibodies in pSS and other autoimmune diseases:
Antinuclear antibodies (ANAs)
Rheumatoid factors (RF)
Anti-centromere antibodies (ACA) (systemic sclerosis)
Anti-mitochondrial antibodies (AMA) - Primary biliary cirrhosis
Anti-cyclic citrullinated peptide antibodies (anti-CCP)
anti-smooth muscle antibodies (ASMA) Autoimmune hepatitis
dsDNA (systemic lupus erythematosus)
Anti- thyreoglobulin (anti TG) – autoimmune thyroiditis
Anti-thyroid peroxidase (anti-TPO)- autoimmune thyroiditis
Novel autoantibodies:
Anti-M3R antibodies
Anti- β fodrin
Anti - protein 1 (SP-1),
Anti - carbonic anhydrase 6 (CA6)
Anti-parotid secretory protein (PSP)
Table 6. Autoantibodies in pSS
Several laboratory tests prove helpful in the diagnosis of pSS, although they do not constitute
a part of the present diagnostic pSS criteria. In particular, the deviations in the composition of
blood cells and proteins occur and the increased erythrocyte sedimentation rate (ESR) with
normal or low concentrations of CRP (a similar situation may exist in multiple myeloma) may
be present. Laboratory findings in pSS are presented in Table 7.
Laboratory findings in pSS
Elevated erythrocyte sedimentation rate (ESR),
leucopenia,
anemia
low platelet count
Hypergammaglobulinemia (polyclonal),
ANAs, RF, anti-Ro/SS-A, anti-B/SSB,
decreased level of complement component C4
Table 7. Laboratory findings in pSS
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7. Prognosis
The emergence of pSS carries an increased risk (by 40 times – comparing to the normal
population) of lymphoma development. This imposes necessity of regular monitoring and
assessment in pSS of factors/markers determining patient’s total capacity for developing
lymphoma, including the emergence of cryoglobulins, rheumatoid factor (if previously not
present) or of monoclonal proteins, chronic enlargement of the salivary glands, or persistent
presence of general symptoms, such as weight loss, fever, and lymphadenopathy.
7.1. Eye examinations for the diagnosis of KCS and pSS
The ophthalmic examination includes first of all a well-known Schirmer’s test used to evaluate
the extent of decrease in the tear secretion.
In the case of significant intensity of dry eye syndrome, the damage to the cornea can be
visualized by applying lissamine green and fluorescein staining [28]. This scoring system has
been proposed for the evaluation of KCS in Sjögren’s syndrome, but applies in general to the
changes in the course of dry eye.
The scoring rules are illustrated in Figure 2, and photographs of eye examination in Figures
3 and 4.
The maximum score for each eye is 12. Scoring more than 3 and higher indicates KCS.
The previous AECG pSS diagnosis criteria consisted, in addition to the Schirmer’s test, in other
tests confirming the presence of KCS and lacrimation disorder, with Bengal rose staining
among the most frequently used. This test allows for the assessment of scaly, dead cells of the
corneal epithelium, and conjunctiva as well as mucus particles (filaments) fixed to the corneal
Llissamine green (conjunctiva) Fluoresceine (cornea)
grade dots grade dots
0 0‐9 0 0
1 10‐32 1 1‐5
2 33‐ 100 2 6‐ 30
3 > 100 3 > 30
For fluoresceine staining the extra 
points could be added : 
+ 1 for patches on confluent staining
+ 1 for  staining in pupilary area
+ 1 for one or more filaments
eye
Temporal area Nasal area
Figure 2. Sicca ocular staining score [25]
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surface, associated with the dry eye syndrome. The results of rose Bengal staining, however,
are dose-dependent and cause phototoxicity. The lissamine green dye is less irritating and thus
considered better for such use. The quality and quantity of the tear film can be evaluated using
tear film break up time (T-BUT)—assessing the time interval between the last complete blink
and the first appearance of a dry spot or of disruption of the tear film, observed in the slit lamp.
The extension of this test uses fluorescein (F-BUT) staining. The diagnosis of DES is established
with BUT result ≤5 seconds. The limitations of this test are eye irritation and increased blink
after fluorescein application as well as difficulty in meeting the condition that the patient can
blink freely [28].
Figure 3. Fluorescein staining
Figure 4. Lissamine green staining
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7.2. Own research
In our study, 30 patients—22 females (73%), 8 males (27%) in mean age of 52 years (from 22 to
85)—diagnosed with pSS revealed stronger correlation of the Schirmer’s test results with FS
than with OSS. The correlation coefficient of OSS with ANA, anti–SS-A, RF was higher than
that of Schirmer’s test with anti–SS-A and RF. OSS correlated negatively with Schirmer’s test
results (r= −0.54; p=0.007). There were no differences between female and male subjects in the
Schirmer’s test, a group of male patients presented more pronounced symptoms of ocular
dryness in the evaluation of staining scores. Our results suggest that the Schirmer’s test reflects
the intensity of ocular gland infiltration by inflammatory cells, whereas immunostaining
proposed in the new Sjögren’s syndrome criteria is more closely associated with the immu‐
noactivity and autoantibodies production. It is obvious that the observed correlation requires
further support and analysis of research performed on a more numerous group of patients.
7.2.1. Statistical analysis
Correlation analyses were performed with the Spearman correlation coefficient (because of
the non-normal distribution of variables). The study was approved by the Bioethics Commis‐
sion of the Institute of Rheumatology; the subjects have signed written informed consent
statements. The study was supported by National Science Center (Narodowe Centrum Nauki)
—grant no. 2012/05/N/NZ5/02838. The correlations are shown in Table 8.
Correlations Correlation coefficient 
(Spearman test) 
N=30 
OSS mean– SS-A 0,17 
OSS mean– SS- B 0,00 
OSS mean – FS 0,13 
OSS mean – RF 0,04 
OSS mean – ANA -0,16 
Schirmer’s test mean –  SS-A -0,10 
Schirmer’s test mean – SS-B 0,14 
Schirmer’s test mean – FS 0,07 
Schirmer’s test mean – RF 0,20 
test Schirmera średnia – ppj -0,01 
SA-A – SS-B  0,56 
OSS mean – Schirmer’s test mean -0,54 
Ro – FS  0,04 
Ro – RF  0,20 
Ro – ppj  0,25 
La – FS  0,07 
La – RF  0,20 
La – ppj  0,27 
 
Table 8. Correlations in patients group with pSS
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The data were presented at the 3rd International Congress on Controversies in Rheumatology
and Autoimmunity in 2014 [29]. Toker et al. [30] also studied the presence of anti–SS/A and
anti–SS/B antibodies in tears and serum as well as assessed the correlations between subjective
and objective clinical score of dry eye (then performed Schirmer's test, TBUT test, and rose
Bengal staining). This study demonstrated that serum titer of anti-Ro/SSA and anti-La/SSB
correlated positively with DESs and negatively with tear production.
7.3. Treatment of pSS
1. Systemic treatment of Sjogren’s syndrome
The therapy of autoimmune diseases, such as pSS, is based on the elimination of inflammation
and inhibition of stimulation of the immune system. Initially, immunosuppressant drugs, such
as corticosteroids, methotrexate, cyclosporine A, and azathioprine are applied. For years, the
effectiveness and relevance of applying antimalaria drugs for the treatment of pSS have been
debated [31–33]. A number of studies confirm beneficial effects of this drug on the symptoms
of dryness and the reduction of BAFF in patients with pSS without significant internal organ
involvement [32–34]. In severe cases with life threatening organ involvement, the use of
cyclophosphamide, infusions of immunoglobulins, and plasmapheresis are considered
necessary.
In the case of renal tubular acidosis, sodium and/or potassium are administered. Considering
the role of B cells in pSS, monoclonal anti-CD20 (rituximab RTX) antibodies seem to be a
favorable option for therapy. RTX has already shown efficacy in the treatment of rheumatoid
arthritis, SLE, and vasculitis [35–37]. The full effectiveness of other biologic drugs causing the
depletion of B cells—such as Belimumab (BLyS/BAFF inhibitor) and epratuzumab (humanized
anti-CD22 monoclonal antibody)—has not yet been confirmed in pSS treatment [38]. The
purpose of the therapy could also be the inhibition of interferon alpha and gamma (IFN-α and
IFN-γ) involved in the stimulation of B cells, but this course of therapy requires further study.
Currently, the use of mesenchymal stem cell (MSC) transplantation as a method of treat‐
ment of various autoimmune diseases, including Sjogren’s syndrome, is also being contem‐
plated [39].
2. Topical treatment—the fight against dryness
Apart from the systemic treatment, no less important for pSS patients is local treatment and
alleviation of dryness symptoms. Firstly, in the case of dry eye, the influence of exacerbating
factors, such as dryness, dust, long hours of working with computer, and smoking, should be
limited. It is recommended to use artificial tears during the day and lubricant ointment at night.
Agents used as preservatives in medical drops, even those in moisturizers- among them:
benzalkonium chloride (BAK) and disodium (EDTA) pose another problem [40]. The use of
over-the-counter (OTC) drops with a higher dose of preservatives increases the symptoms of
dryness [41].
The wide array of medications is being used in topical treatment: eye lubricants and moistur‐
izers, such as drops, gels, ointments containing tear substitutes, oils and petrolatum, acrylic
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acid, hyaluronic acid, glycerin, erythritol, levocarnitine, hydroxymethylcellose, carboxyme‐
thylcelulose, or glycol. The preparations without preservatives that replace tears include, e.g.,
Refresh (Allergan), TheraTears, Soothe (Bausch + Lomb), and System (Alcon) [41].
Ocular lubricants and moisturizers are designed to supplement the shortage of tears, osmo‐
larity, and to improve tear film stability and act protectively. A patient with severe DES both
in the course of PSS and from other causes, however, should consult the use of these substances
with an ophthalmologist. Increasing the amount of tears can be achieved by permanent
occluding of nasolacrimal channel and by the use of biological tear substitutes, namely a drop
of the patient’s own serum. The inflammatory process in the course KCS also requires anti-
inflammatory therapy with cyclosporine drops and topical glucocorticoids. Research is being
conducted on the use of pimecrolimus and tacrolimus as immunomodulatory drugs in drops.
Also drugs stimulating tear secretion with cholinergic agonists are being used and two of them,
namely pilocarpine and cevimeline, are used widely. Currently, studies are being carried out
on other stimulants, among others diquafosol (P2Y2 receptor agonist) and rebamipide [42,43].
Tetracyclines (minocycline, tetracycline) might also be considered as important drugs for pSS
therapy, showing both antibacterial and immunomodulating effect. They have greater than
just antimicrobial effect on inflammation by inhibiting the proinflammatory cytokines as TNF
or interleukin-1 (IL-1) and also inhibiting angiogenesis. They have been applied to treat eye
infections, ocular and skin manifestations of acne rosacea and are used in the case of meibo‐
mian gland dysfunction [44]. In the case of complications of bacterial infection in the course
of KCS, typical antibiotics covering the activities of most common pathogens are being used.
These include aminoglycosides (e.g., Tobramycin), macrolides, fluoroquinolones, sodium
sulfacetamide, or trimethoprim/polymyxin. While wearing contact lenses is as a possible cause
of dry eye, in the treatment of DES contact lenses made of special materials such as silicone
rubber and highly oxygen permeable materials may protect the eye from drying [45,46].
The surgical treatment, including placement of punctual plugs (collagen or silicone) and
cauterization of the puncta, is used in cases of severe corneal injuries and at a risk of a loss of
vision. The transplantation of minor salivary glands is an interesting and promising method,
but so far with limited use as a therapeutic option [47]. The salivary glands are transplanted
as a complex graft to the posterior lamella of the eyelids to increase an ocular surface lubrication
and reduce a discomfort in dry eyes.
Frequent blinking is also important for the prophylaxis and complementary action treatment
for symptoms of dry eye; avoiding situations that increase the evaporation of the tear film (e.g.
wind, air conditioning, and smoking) is recommended as well. The patients with pSS and
symptoms of dry eye should be controlled both by a rheumatologist and an ophthalmologist.
Routine check of a dry eye should take place at least once every 3 months. However ophthal‐
mologic monitoring frequency will depend on the severity of DESs and the presence of dry
eye complications, such as infections. In the latter case, the control should be performed every
few days until the infection is cured. The aim of the topical therapy is to eliminate symptoms
of dryness and to directly protect mucous membranes. The systemic treatment is directed at
achieving a remission—the inhibition of the disease progress, changes in internal organs, and
inflammation and infiltration of exocrine glands.
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8. Summary
The Sjögren’s syndrome is one of the most common rheumatic diseases with predominant
symptoms of dryness, particularly of the eye. Therefore, the knowledge on dry eye disease or
KCS symptoms is essential not only for ophthalmologic but also for rheumatologic practice.
The above section certainly does not exhaust the problem of Sjögren’s syndrome, its intricate
and still uncertain pathogenesis and a differentiated clinical picture. The author’s intention
was primarily to draw attention to the problem of DESs and associated complications,
including infections.
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